Furthermore, prostate cancer patients were classified into four different immune subtypes (C1, C2, C3, and C4), and EXO1 expression was found to be the lowest in the C3 subtype (Additional file 2: Fig. S2J). Here, EXO1 is linked to prostate carcinoma.